GYRE Form 3: Director Dan Weng Reports No Beneficial Ownership

Gyre Therapeutics director Dan Weng filed an SEC Form 3 disclosing no beneficial ownership of Gyre Therapeutics, Inc. (GYRE) common stock.

Rhea-AI Filing Summary

Gyre Therapeutics director Dan Weng filed an SEC Form 3 disclosing no beneficial ownership of Gyre Therapeutics, Inc. (GYRE) common stock. The filing, dated 08/18/2025 for the event and signed 08/26/2025 by an attorney-in-fact, lists Weng's San Diego office address and indicates the report was filed by one reporting person. The filing includes Exhibit 24 (Power of Attorney).

Positive

• Reporting person complied with Section 16 filing requirements
• Form clearly states 'No securities are beneficially owned,' removing ambiguity about immediate insider holdings
• Includes Exhibit 24 (Power of Attorney), ensuring proper authorization of the filing

Negative

• None.

Insights

Corporate Governance Expert

TL;DR: Routine initial Section 16 filing; director reports no beneficial ownership, showing no immediate insider holdings to monitor.

The Form 3 is an initial ownership disclosure required when an individual becomes a reporting person. It identifies Dan Weng as a director and states explicitly that no securities are beneficially owned. The filing includes a Power of Attorney (Exhibit 24) and was signed by an attorney-in-fact, which is a common administrative practice. Impact on governance oversight is minimal because no insider position is reported.

Securities Analyst

TL;DR: Material impact is neutral; absence of holdings means no immediate insider buying or selling signal from this filing.

From a market-signaling perspective, the Form 3 contains no equity position to analyze. The document provides basic identifying information (address, director status) and the event date of 08/18/2025. Because there are no derivative or non-derivative securities reported, there is no effect on share count or insider concentration disclosed here.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Dan Weng report on the Form 3 for GYRE?

The Form 3 states no securities are beneficially owned by Dan Weng and identifies him as a director.

When is the event date reported on the GYRE Form 3?

The Date of Event Requiring Statement is 08/18/2025.

Was the Form 3 signed, and if so by whom?

Yes. The form was signed /s/ Ruoyu Chen, as attorney-in-fact for Dan Weng on 08/26/2025.

Does the filing include any exhibits?

Yes. The filing references Exhibit 24 - Power of Attorney.

What is the reporting person’s listed address on the Form 3?

The address listed is c/o Gyre Therapeutics, Inc., 12770 High Bluff Drive, Suite 150, San Diego, CA 92130.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/26/2025 - 04:03 PM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Weng Dan

(Last) (First) (Middle)

C/O GYRE THERAPEUTICS, INC.

12770 HIGH BLUFF DRIVE, SUITE 150

(Street)

SAN DIEGO CA 92130

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
08/18/2025

3. Issuer Name and Ticker or Trading Symbol
GYRE THERAPEUTICS, INC. [ GYRE ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ Ruoyu Chen, as attorney-in-fact for Dan Weng	08/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.